Respiratory system involvement in brucellosis: the results of the Kardelen study
Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis. This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respirat...
Gespeichert in:
Veröffentlicht in: | Chest 2014-01, Vol.145 (1), p.87-94 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 94 |
---|---|
container_issue | 1 |
container_start_page | 87 |
container_title | Chest |
container_volume | 145 |
creator | Erdem, Hakan Inan, Asuman Elaldi, Nazif Tekin, Recep Gulsun, Serda Ataman-Hatipoglu, Cigdem Beeching, Nicholas Deveci, Özcan Yalci, Aysun Bolukcu, Sibel Dagli, Ozgur |
description | Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis.
This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respiratory system involvement.
Of 133 patients (67 men), 123 (92.5%) had acute infection (defined as < 2 months), with an overall mean ± SD duration of symptoms of 33.9 ± 8.5 days. The radiologic pattern of pulmonary disease was consolidation/lobar pneumonia in 91 patients (68.4%) and pleural effusion in 41 patients (30.8%), including 30 (22.5%) with both. Moreover, 23 patients (17.3%) had bronchitis (one with coexistent pneumonia), and 10 (7.5%) had nodular lung lesions (one with coexistent pneumonia and effusion). Blood culture results were positive in 56 of 119 patients, and all other cases were serologically confirmed. None of 60 sputum specimens and two of 19 pleural fluid samples (10.5%) yielded positive culture results for brucellosis. Other features of brucellosis, such as osteoarticular complications, were detected in 61 patients (45.9%); 59 (44.4%) had raised liver transaminase levels, and 59 (44.4%) had thrombocytopenia. Fifteen patients (11.3%) required management in an ICU for an average of 3.8 ± 2.2 days. All patients responded to standard combination antimicrobial therapy for brucellosis with no deaths, although treatment regimens required modification in seven patients.
Brucellosis with pulmonary involvement is rare but has a good prognosis following treatment with appropriate antibiotics. Many clues in the exposure history, presenting clinical features, and baseline blood tests should alert the clinician to consider brucellosis. |
doi_str_mv | 10.1378/chest.13-0240 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490703671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490703671</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-b217882f2e843096b6e9032a707fecae989db752c6f6e1c32b5928853be2a9503</originalsourceid><addsrcrecordid>eNo1UEtLxDAYDIK46-rRq-TopZpH2yTeZHFVXFBEzyVpv7KVvsyXLPTfW3U9zQwMw8wQcsHZNZdK35Q7wDDThImUHZElN5InMkvlgpwifjLGODf5CVkIaZiSSizJ6xvg2HgbBj9RnDBAR5t-P7R76KAPM6fOxxLadsAGb2nYAfWAsQ1Ih_pXPltfQQs9xRCr6Ywc17ZFOD_ginxs7t_Xj8n25eFpfbdNRsF5SJzgSmtRC9CpZCZ3ORgmhVVM1VBaMNpUTmWizOsceCmFy4zQOpMOhDUZkyty9Zc7-uErzruLrsGfnraHIWLB03kik7nis_XyYI2ug6oYfdNZPxX_L8hvYStdaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490703671</pqid></control><display><type>article</type><title>Respiratory system involvement in brucellosis: the results of the Kardelen study</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Erdem, Hakan ; Inan, Asuman ; Elaldi, Nazif ; Tekin, Recep ; Gulsun, Serda ; Ataman-Hatipoglu, Cigdem ; Beeching, Nicholas ; Deveci, Özcan ; Yalci, Aysun ; Bolukcu, Sibel ; Dagli, Ozgur</creator><creatorcontrib>Erdem, Hakan ; Inan, Asuman ; Elaldi, Nazif ; Tekin, Recep ; Gulsun, Serda ; Ataman-Hatipoglu, Cigdem ; Beeching, Nicholas ; Deveci, Özcan ; Yalci, Aysun ; Bolukcu, Sibel ; Dagli, Ozgur ; Brucellosis Study Group</creatorcontrib><description>Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis.
This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respiratory system involvement.
Of 133 patients (67 men), 123 (92.5%) had acute infection (defined as < 2 months), with an overall mean ± SD duration of symptoms of 33.9 ± 8.5 days. The radiologic pattern of pulmonary disease was consolidation/lobar pneumonia in 91 patients (68.4%) and pleural effusion in 41 patients (30.8%), including 30 (22.5%) with both. Moreover, 23 patients (17.3%) had bronchitis (one with coexistent pneumonia), and 10 (7.5%) had nodular lung lesions (one with coexistent pneumonia and effusion). Blood culture results were positive in 56 of 119 patients, and all other cases were serologically confirmed. None of 60 sputum specimens and two of 19 pleural fluid samples (10.5%) yielded positive culture results for brucellosis. Other features of brucellosis, such as osteoarticular complications, were detected in 61 patients (45.9%); 59 (44.4%) had raised liver transaminase levels, and 59 (44.4%) had thrombocytopenia. Fifteen patients (11.3%) required management in an ICU for an average of 3.8 ± 2.2 days. All patients responded to standard combination antimicrobial therapy for brucellosis with no deaths, although treatment regimens required modification in seven patients.
Brucellosis with pulmonary involvement is rare but has a good prognosis following treatment with appropriate antibiotics. Many clues in the exposure history, presenting clinical features, and baseline blood tests should alert the clinician to consider brucellosis.</description><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.13-0240</identifier><identifier>PMID: 23907372</identifier><language>eng</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Bronchitis - diagnosis ; Bronchitis - drug therapy ; Brucellosis - diagnosis ; Brucellosis - drug therapy ; Ceftriaxone ; Doxycycline - therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Pleural Effusion - diagnosis ; Pleural Effusion - drug therapy ; Pneumonia - diagnosis ; Pneumonia - drug therapy ; Prognosis ; Retrospective Studies ; Rifampin - therapeutic use ; Streptomycin - therapeutic use ; Turkey ; Young Adult</subject><ispartof>Chest, 2014-01, Vol.145 (1), p.87-94</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23907372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Erdem, Hakan</creatorcontrib><creatorcontrib>Inan, Asuman</creatorcontrib><creatorcontrib>Elaldi, Nazif</creatorcontrib><creatorcontrib>Tekin, Recep</creatorcontrib><creatorcontrib>Gulsun, Serda</creatorcontrib><creatorcontrib>Ataman-Hatipoglu, Cigdem</creatorcontrib><creatorcontrib>Beeching, Nicholas</creatorcontrib><creatorcontrib>Deveci, Özcan</creatorcontrib><creatorcontrib>Yalci, Aysun</creatorcontrib><creatorcontrib>Bolukcu, Sibel</creatorcontrib><creatorcontrib>Dagli, Ozgur</creatorcontrib><creatorcontrib>Brucellosis Study Group</creatorcontrib><title>Respiratory system involvement in brucellosis: the results of the Kardelen study</title><title>Chest</title><addtitle>Chest</addtitle><description>Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis.
This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respiratory system involvement.
Of 133 patients (67 men), 123 (92.5%) had acute infection (defined as < 2 months), with an overall mean ± SD duration of symptoms of 33.9 ± 8.5 days. The radiologic pattern of pulmonary disease was consolidation/lobar pneumonia in 91 patients (68.4%) and pleural effusion in 41 patients (30.8%), including 30 (22.5%) with both. Moreover, 23 patients (17.3%) had bronchitis (one with coexistent pneumonia), and 10 (7.5%) had nodular lung lesions (one with coexistent pneumonia and effusion). Blood culture results were positive in 56 of 119 patients, and all other cases were serologically confirmed. None of 60 sputum specimens and two of 19 pleural fluid samples (10.5%) yielded positive culture results for brucellosis. Other features of brucellosis, such as osteoarticular complications, were detected in 61 patients (45.9%); 59 (44.4%) had raised liver transaminase levels, and 59 (44.4%) had thrombocytopenia. Fifteen patients (11.3%) required management in an ICU for an average of 3.8 ± 2.2 days. All patients responded to standard combination antimicrobial therapy for brucellosis with no deaths, although treatment regimens required modification in seven patients.
Brucellosis with pulmonary involvement is rare but has a good prognosis following treatment with appropriate antibiotics. Many clues in the exposure history, presenting clinical features, and baseline blood tests should alert the clinician to consider brucellosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bronchitis - diagnosis</subject><subject>Bronchitis - drug therapy</subject><subject>Brucellosis - diagnosis</subject><subject>Brucellosis - drug therapy</subject><subject>Ceftriaxone</subject><subject>Doxycycline - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pleural Effusion - diagnosis</subject><subject>Pleural Effusion - drug therapy</subject><subject>Pneumonia - diagnosis</subject><subject>Pneumonia - drug therapy</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Rifampin - therapeutic use</subject><subject>Streptomycin - therapeutic use</subject><subject>Turkey</subject><subject>Young Adult</subject><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UEtLxDAYDIK46-rRq-TopZpH2yTeZHFVXFBEzyVpv7KVvsyXLPTfW3U9zQwMw8wQcsHZNZdK35Q7wDDThImUHZElN5InMkvlgpwifjLGODf5CVkIaZiSSizJ6xvg2HgbBj9RnDBAR5t-P7R76KAPM6fOxxLadsAGb2nYAfWAsQ1Ih_pXPltfQQs9xRCr6Ywc17ZFOD_ginxs7t_Xj8n25eFpfbdNRsF5SJzgSmtRC9CpZCZ3ORgmhVVM1VBaMNpUTmWizOsceCmFy4zQOpMOhDUZkyty9Zc7-uErzruLrsGfnraHIWLB03kik7nis_XyYI2ug6oYfdNZPxX_L8hvYStdaQ</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Erdem, Hakan</creator><creator>Inan, Asuman</creator><creator>Elaldi, Nazif</creator><creator>Tekin, Recep</creator><creator>Gulsun, Serda</creator><creator>Ataman-Hatipoglu, Cigdem</creator><creator>Beeching, Nicholas</creator><creator>Deveci, Özcan</creator><creator>Yalci, Aysun</creator><creator>Bolukcu, Sibel</creator><creator>Dagli, Ozgur</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201401</creationdate><title>Respiratory system involvement in brucellosis: the results of the Kardelen study</title><author>Erdem, Hakan ; Inan, Asuman ; Elaldi, Nazif ; Tekin, Recep ; Gulsun, Serda ; Ataman-Hatipoglu, Cigdem ; Beeching, Nicholas ; Deveci, Özcan ; Yalci, Aysun ; Bolukcu, Sibel ; Dagli, Ozgur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-b217882f2e843096b6e9032a707fecae989db752c6f6e1c32b5928853be2a9503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bronchitis - diagnosis</topic><topic>Bronchitis - drug therapy</topic><topic>Brucellosis - diagnosis</topic><topic>Brucellosis - drug therapy</topic><topic>Ceftriaxone</topic><topic>Doxycycline - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pleural Effusion - diagnosis</topic><topic>Pleural Effusion - drug therapy</topic><topic>Pneumonia - diagnosis</topic><topic>Pneumonia - drug therapy</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Rifampin - therapeutic use</topic><topic>Streptomycin - therapeutic use</topic><topic>Turkey</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erdem, Hakan</creatorcontrib><creatorcontrib>Inan, Asuman</creatorcontrib><creatorcontrib>Elaldi, Nazif</creatorcontrib><creatorcontrib>Tekin, Recep</creatorcontrib><creatorcontrib>Gulsun, Serda</creatorcontrib><creatorcontrib>Ataman-Hatipoglu, Cigdem</creatorcontrib><creatorcontrib>Beeching, Nicholas</creatorcontrib><creatorcontrib>Deveci, Özcan</creatorcontrib><creatorcontrib>Yalci, Aysun</creatorcontrib><creatorcontrib>Bolukcu, Sibel</creatorcontrib><creatorcontrib>Dagli, Ozgur</creatorcontrib><creatorcontrib>Brucellosis Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erdem, Hakan</au><au>Inan, Asuman</au><au>Elaldi, Nazif</au><au>Tekin, Recep</au><au>Gulsun, Serda</au><au>Ataman-Hatipoglu, Cigdem</au><au>Beeching, Nicholas</au><au>Deveci, Özcan</au><au>Yalci, Aysun</au><au>Bolukcu, Sibel</au><au>Dagli, Ozgur</au><aucorp>Brucellosis Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Respiratory system involvement in brucellosis: the results of the Kardelen study</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2014-01</date><risdate>2014</risdate><volume>145</volume><issue>1</issue><spage>87</spage><epage>94</epage><pages>87-94</pages><eissn>1931-3543</eissn><abstract>Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis.
This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respiratory system involvement.
Of 133 patients (67 men), 123 (92.5%) had acute infection (defined as < 2 months), with an overall mean ± SD duration of symptoms of 33.9 ± 8.5 days. The radiologic pattern of pulmonary disease was consolidation/lobar pneumonia in 91 patients (68.4%) and pleural effusion in 41 patients (30.8%), including 30 (22.5%) with both. Moreover, 23 patients (17.3%) had bronchitis (one with coexistent pneumonia), and 10 (7.5%) had nodular lung lesions (one with coexistent pneumonia and effusion). Blood culture results were positive in 56 of 119 patients, and all other cases were serologically confirmed. None of 60 sputum specimens and two of 19 pleural fluid samples (10.5%) yielded positive culture results for brucellosis. Other features of brucellosis, such as osteoarticular complications, were detected in 61 patients (45.9%); 59 (44.4%) had raised liver transaminase levels, and 59 (44.4%) had thrombocytopenia. Fifteen patients (11.3%) required management in an ICU for an average of 3.8 ± 2.2 days. All patients responded to standard combination antimicrobial therapy for brucellosis with no deaths, although treatment regimens required modification in seven patients.
Brucellosis with pulmonary involvement is rare but has a good prognosis following treatment with appropriate antibiotics. Many clues in the exposure history, presenting clinical features, and baseline blood tests should alert the clinician to consider brucellosis.</abstract><cop>United States</cop><pmid>23907372</pmid><doi>10.1378/chest.13-0240</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1931-3543 |
ispartof | Chest, 2014-01, Vol.145 (1), p.87-94 |
issn | 1931-3543 |
language | eng |
recordid | cdi_proquest_miscellaneous_1490703671 |
source | MEDLINE; Journals@Ovid Complete; Alma/SFX Local Collection |
subjects | Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use Bronchitis - diagnosis Bronchitis - drug therapy Brucellosis - diagnosis Brucellosis - drug therapy Ceftriaxone Doxycycline - therapeutic use Drug Therapy, Combination Female Humans Male Middle Aged Pleural Effusion - diagnosis Pleural Effusion - drug therapy Pneumonia - diagnosis Pneumonia - drug therapy Prognosis Retrospective Studies Rifampin - therapeutic use Streptomycin - therapeutic use Turkey Young Adult |
title | Respiratory system involvement in brucellosis: the results of the Kardelen study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A02%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Respiratory%20system%20involvement%20in%20brucellosis:%20the%20results%20of%20the%20Kardelen%20study&rft.jtitle=Chest&rft.au=Erdem,%20Hakan&rft.aucorp=Brucellosis%20Study%20Group&rft.date=2014-01&rft.volume=145&rft.issue=1&rft.spage=87&rft.epage=94&rft.pages=87-94&rft.eissn=1931-3543&rft_id=info:doi/10.1378/chest.13-0240&rft_dat=%3Cproquest_pubme%3E1490703671%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490703671&rft_id=info:pmid/23907372&rfr_iscdi=true |